Review article · 2022 · Open access
A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020
Frontiers in Medicine, 9, 968272 · Published 12 August 2022 · DOI 10.3389/fmed.2022.968272
In brief
“A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020” is a 2022 review article by Maria Manuel Teixeira and 5 co-authors, published in Frontiers in Medicine. OpenAlex counts 48 citations as of 22 November 2026, which puts it in the top 8% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Medicine.
- Citations
- 48
- Most cited in
- 2025 (14)
- Field-weighted impact
- 1.23
- References
- 49
- Authors
- 6
Abstract
Introduction: Cancer and corresponding available treatments are associated with substantial symptoms and functional limitations. In this context, collection of patient-reported outcomes (PRO) in clinical trials gained special interest and is recommended by regulatory authorities. Within clinical trials framework, PRO may provide evidence to support medicines approval, labeling and marketing claims. This study aims to analyze the existing evidence based on PRO as part of new oncology indications receiving positive opinions issued by the European Medicines Agency (EMA) between 2017 and 2020 and to identify PRO related label claims granted. Methodology: Oncology medicinal products and indications approved by the European Commission following a positive opinion from the EMA between 2017 and 2020 were identified. European Public Assessment Report (EPAR) and Summary of Product Characteristics (SmPC) were reviewed for each medicinal product to identify use of PRO and PRO label claims. Results: A total of 128 oncology indications, corresponding to 76 medicines, were approved; of those, 100 (78.1%) included PRO in the confirmatory clinical trials. Thirty-seven indications were supported by double-blind randomized trials and the remainder 63 by open-label trials. Out of the 104 confirmatory trials analyzed, PRO were defined as a secondary endpoint in 60 studies (57.7%), exploratory in 31 (29.8%) and as both in 13 (12.5%). In total, 54 different PRO measures (PROM) were used, of those 41 (75.9%) were disease-specific measures. Nevertheless, PROM selected relied on the EORTC (41.3%), FACIT (17.1%) and EQ-5D (29.2%) measures. A total of 76 indications (59.4%) had PRO reviewers comments included in the EPAR, however only 22 indications (17.8%) included label claims in the SmPC. The reasons identified in the EMA assessment supporting the exclusion of PRO claims were described for 34 indications (44.7%). Conclusions: Despite growing recognition of the value of PRO data for the development of improved cancer therapies, PRO implementation remains challenging. The main reasons identified in our study are related with study design, missing data, study conduct and PROM selection.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Teixeira, M. M., Borges, F. C., Ferreira, P. B. S., Rocha, J. P., Sepodes, B. M. N., & Torre, C. (2022). A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020. Frontiers in Medicine, 9, 968272. https://doi.org/10.3389/fmed.2022.968272
MLA 9
Teixeira, Maria Manuel, et al. “A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.” Frontiers in Medicine, vol. 9, 2022, p. 968272. https://doi.org/10.3389/fmed.2022.968272.
Chicago
Teixeira, Maria Manuel, Fábio Cardoso Borges, Paula Barão Sousa Ferreira, João Pedro Rocha, Bruno Miguel Nogueira Sepodes, and Carla Torre. 2022. “A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020.” Frontiers in Medicine 9: 968272. https://doi.org/10.3389/fmed.2022.968272.
Harvard
Teixeira, M. M. et al. (2022) ‘A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020’, Frontiers in Medicine, 9, p. 968272. doi:10.3389/fmed.2022.968272.
IEEE
M. M. Teixeira, F. C. Borges, P. B. S. Ferreira, J. P. Rocha, B. M. N. Sepodes, and C. Torre, “A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020,” Frontiers in Medicine, vol. 9, p. 968272, 2022, doi: 10.3389/fmed.2022.968272.
BibTeX
@article{teixeira2022review,
title = {{A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020}},
author = {Teixeira, Maria Manuel and Borges, Fábio Cardoso and Ferreira, Paula Barão Sousa and Rocha, João Pedro and Sepodes, Bruno Miguel Nogueira and Torre, Carla},
journal = {Frontiers in Medicine},
year = {2022},
volume = {9},
pages = {968272},
doi = {10.3389/fmed.2022.968272},
url = {https://doi.org/10.3389/fmed.2022.968272}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 2 | |
| 2023 | 8 | |
| 2024 | 12 | |
| 2025 | 14 | |
| 2026 | 12 |
Its field-weighted citation impact is 1.23: it has been cited 1.23 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- patient-reported outcomes
- regulatory approval
- European Medicines Agency
- European Public Assessment Reports
- Summary of Product Characteristics
- label claims
- confirmatory trials
- EORTC
Work with this paper
Most-cited papers in Economics, Econometrics and Finance
- Theory of the firm: Managerial behavior, agency costs and ownership structureMichael C. Jensen, William H. Meckling · Journal of Financial Economics · 1976 · 77,585 citations
- Institutions, Institutional Change and Economic PerformanceDouglass C. North · Cambridge University Press eBooks · 1990 · 34,377 citations
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.John E. Ware, Cathy Donald Sherbourne · PubMed · 1992 · 33,943 citations
- Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment EquationsManuel Arellano, Stephen R. Bond · The Review of Economic Studies · 1991 · 33,778 citations
- Co-Integration and Error Correction: Representation, Estimation, and TestingRobert F. Engle, C.W.J. Granger · Econometrica · 1987 · 32,847 citations
Questions about this paper
How do I cite this paper in APA style?
Teixeira, M. M., Borges, F. C., Ferreira, P. B. S., Rocha, J. P., Sepodes, B. M. N., & Torre, C. (2022). A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020. Frontiers in Medicine, 9, 968272. https://doi.org/10.3389/fmed.2022.968272
How many times has this paper been cited?
48 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Maria Manuel Teixeira, Fábio Cardoso Borges, Paula Barão Sousa Ferreira, João Pedro Rocha, Bruno Miguel Nogueira Sepodes, Carla Torre.
What is the DOI of this paper?
10.3389/fmed.2022.968272, permanently at https://doi.org/10.3389/fmed.2022.968272. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.